Compare Boston Scientific Corporation (BSX) vs 8x8 Inc (EGHT) Price & Performance

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

EGHT trades at $2.30, up 1.1% today, with a bullish technical signal from moving averages. The company shows strong revenue growth, with five consecutive quarters of year-over-year increases, and has beaten EPS estimates in recent quarters. Recent news highlights the launch of a new partner program and expansion of AI capabilities across its platform. However, the stock carries a high P/E ratio of 74.67, and the company reported a net loss of $27.21 million for 2025.

The outlook is cautiously optimistic, with analyst consensus pointing to significant upside with a $3.13 price target. Key opportunities include sustained revenue growth and AI-driven product expansion, while risks involve high valuation, debt levels, and the challenge of achieving consistent profitability. Institutional sentiment is mixed but leans positive.